Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Dolly Sharma, PhD
Advertisement
Articles by Dolly Sharma, PhD
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5